1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Austria Pharmaceuticals and Healthcare Report Q1 2017

Austria Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 63 pages

Includes 3 FREE quarterly updates


>BMI View:
Austria's skilled workforce and location at the heart of Europe would make it ideal as a manufacturing hub, but the country has largely been surpassed by neighbouring Germany and Switzerland in terms of pharmaceutical manufacturing. Whereas big pharmaceutical companies dominate in terms of revenues and manufacturing capacity in Germany and Switzerland, most local companies in Austria are small-medium enterprises with relatively small revenue streams. Austria is home to a burgeoning biotech industry with local companies becoming acquisition targets for foreign drugmakers.

Headline Expenditure Projections

- Pharmaceuticals: EUR6.29bn (USD6.97bn) in 2015 to EUR6.48bn (USD6.94bn) in 2016; 3.15% in local currency terms and -0.5% in US dollar terms. Forecasts unchanged from the previous quarter.

- Healthcare: EUR38.4bn (USD42.6bn) in 2015 to EUR40.0bn (USD42.8bn) in 2016; +4.2% in local currency terms and 0.5% in US dollar terms. Forecasts increased from the previous quarter. In our Q1 2017 Pharmaceutical Risk/Reward Index (RRI) we have awarded Austria a score of 75.0, up from 73.8 in the previous quarter, which means that Austria ranks second in the region (up from the third place in the previous quarter) and scores only below Germany. Notably, Austria holds one of the highest RRI scores globally due to the inherent rewards and low risks that arise from an ageing population, high per capita spending and stable policy environment for drugmakers operating in the country.

Table Of Contents

Austria Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Austria 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Austria 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Austria 2012-2020) 18
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Austria 2012-2020) 20
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Austria 2012-2020) 22
OTC Drug Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Austria 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Austria 2014-2020) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Austria 2014-2020) 26
Industry Risk/Reward Index 27
Western Europe Risk/Reward Index 27
Austria Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Intellectual Property Issues 36
Pricing Regime 36
Reimbursement Regime 37
Market Overview 39
Healthcare Sector 40
Table: Healthcare Resources (Austria 2010-2015) 41
Table: Healthcare Personnel (Austria 2010-2015) 41
Table: Healthcare Activity (Austria 2010-2015) 42
Research And Development 42
Clinical Trials 43
Epidemiology 44
Competitive Landscape 46
Research-Based Industry 46
Table: Multinational Market Activity 46
Pharmaceutical Distribution 48
Table: Members Of ARGE Pharmazeutika, 2011 48
Pharmaceutical Retail Sector 50
Table: Pharmacy Outlets by Type, 2005-2009 51
Table: Pharmacy Outlets by State, 2005-2009 51
Demographic Forecast 52
Table: Population Headline Indicators (Austria 1990-2025) 53
Table: Key Population Ratios (Austria 1990-2025) 53
Table: Urban/Rural Population and Life Expectancy (Austria 1990-2025) 54
Table: Population By Age Group (Austria 1990-2025) 54
Table: Population By Age Group % (Austria 1990-2025) 55
Glossary 57
Methodology 59
Pharmaceutical Expenditure Forecast Model 59
Healthcare Expenditure Forecast Model 59
Notes On Methodology 60
Risk/Reward Index Methodology 61
Index Overview 62
Table: Pharmaceutical Risk/Reward Index Indicators 62
Indicator Weightings 63

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.